^
Association details:
| Biomarker: | PTPN2 amplification |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ERBB2 and PTPN2 g ene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab
Excerpt:
In the multiple Cox analysis, high-grade ERBB2 amplification was significantly associated with improved prognosis both in terms of OS and PFS. In contrast, PTPN2 gain was significantly associated with shorter OS and PFS.
DOI:
10.3892/ol.2019.9998